Business Wire

SINOVAC-BIOTECH

6.9.2022 12:01:43 CEST | Business Wire | Press release

Share
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac®, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine.

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited. Participants belonging to the heterologous scheme are individuals who had received two CoronaVac® doses, and two boosters of mRNA-based or viral vector-based vaccines, while participants of the homologous scheme had received four doses of CoronaVac®. Individuals from the heterologous scheme will randomly receive a booster dose with the Omicron, Trivalent, or CoronaVac® vaccines, while individuals from the homogeneous group will randomly receive a booster dose of the Omicron or the trivalent vaccines.

Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, “SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine. We are proud of the fact that CoronaVac® can protect individuals as young as 6 months of age and this clinical approval will allow even better vaccine protection.”

About SINOVAC

Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis. Its COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. Its Healive®, hepatitis A vaccine, passed WHO prequalification requirements in 2017. Its EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005511/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa Threats Report: As Network Security Strengthens, Criminals Accelerate Shift to AI-Enabled Social Engineering20.5.2026 15:16:00 CEST | Press release

Spring 2026 Biannual Threats Report shows how strengthening payment security is pushing criminals toward AI-enabled social engineering Visa (NYSE: V), a world leader in digital payments, today released its Spring 2026 Biannual Threats Report, revealing that scams have become the fastest-growing source of consumer harm as criminals increasingly use artificial intelligence and social engineering to manipulate people into authorizing payments themselves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520153924/en/ The report draws on intelligence from Visa’s global network and underscores a critical shift in the fraud landscape: while core payment security continues to strengthen at the network level, criminals are redirecting their efforts away from technical system compromises toward exploiting human trust. From July to December 2025, Visa identified nearly $1 billion in scam-related activity, making scams the single large

1GLOBAL Launches Verint Communications Analytics to Enhance Cloud Compliance for Financial and Regulated Industries20.5.2026 15:00:00 CEST | Press release

1GLOBAL now offers transcription with insights into mobile calls in 10 countries on Verint Communications Analytics, built specifically for financial markets and trading environmentsStreamlines the compliance investigation and mobile call monitoring process through transcription and analysisSupports transcription and translation from 30+ languages into English with near real-time processing 1GLOBAL, a pioneer in global telecommunications solutions, today announced its launch of Verint® Communications Analytics, a key offering within Verint Financial Compliance (VFC) providing mobile call transcription and analytics capabilities. Verint Communications Analytics has been designed to help financial institutions and regulated organizations accelerate productivity when monitoring voice calls (including mobile), identifying behavioral patterns, querying data intentionally by topic, risks, keywords or sentiment, identifying misuse and reducing regulatory risk. Verint Communications Analytics

Xsolla Expands Nordic Presence With Industry Engagements Across Sweden, Including Official Sponsorship of Nordic Game 202620.5.2026 15:00:00 CEST | Press release

Coordinated Activations Across Sweden Underscore Xsolla’s Continued Investment In The Nordic Games Ecosystem, Bringing Developers, Partners, And Creators Together Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of events and activations across Sweden throughout May 2026, including its official sponsorship of Nordic Game 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520833786/en/ Graphic: Xsolla At Nordic Game, Xsolla will showcase its Web Shop solution, a direct-to-consumer (D2C) platform designed to help developers build and scale their own storefronts outside traditional app stores. The Web Shop ecosystem integrates storefronts, LiveOps tools, and player engagement features, enabling studios to strengthen player relationships while increasing revenue and operational control. Xsolla will also highlight its global pay

Cyclic Materials Appoints Former Siemens and Alcoa CEO Klaus Kleinfeld to Board of Directors20.5.2026 14:30:00 CEST | Press release

Dr. Klaus Kleinfeld’s proven leadership at two Fortune 500 public companies will strengthen the company’s global expansion Cyclic Materials, the rare earth recycling company enabling domestic circular supply chain for critical materials around the world, today announced the appointment of Dr. Klaus Kleinfeld to its Board of Directors. Dr. Kleinfeld brings decades of experience leading global industrial and advanced manufacturing businesses, including serving as CEO of two Fortune 500 companies – Siemens AG and Alcoa. His experience growing complex international operations, navigating global markets, and leading large industrial transformations will support Cyclic Materials’ industrial expansion to meet an accelerating global demand. An internationally recognized executive, investor, and entrepreneur, Dr. Kleinfeld has advised multiple U.S. Presidents and global leaders on industrial competitiveness, technology, and economic development. “Cyclic Materials is scaling a strategically vita

HTEC and Motion Applied: Collaboration Built on Performance, Precision, and Innovation20.5.2026 14:18:00 CEST | Press release

HTEC, a global AI-first engineering and digital product development company, and Motion Applied are expanding their collaboration following a successful track record in developing advanced solutions across multiple industries. Motion Applied delivers engineering and technology solutions in motorsport, electrification and transportation, bringing 35 years of top-tier motorsport heritage and race-honed engineering excellence to the development of high-performance systems and their application beyond the track. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520285726/en/ HTEC, a global AI-first engineering and digital product development company, and Motion Applied are expanding their collaboration following a successful track record in developing advanced solutions for the motorsport and transportation industry. The two companies have worked closely on complex engineering initiatives, contributing to the advancement of high

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye